If your institution subscribes to this resource, and you don't have a MyAccess Profile, please contact your library's reference desk for information on how to gain access to this resource from off-campus.
Antineoplastic, multikinase inhibitor
BRAF-positive (V600E or V600K) metastatic melanoma† (in combination with binimetinib)
Chapter 67. Pathway-Targeted Therapies: Monoclonal Antibodies, Protein Kinase Inhibitors, and Various Small Molecules > Inhibitors of RAF Kinase: Vemurafenib, Dabrafenib
eChapter 2018: The Goodman & Gilman Year in Review New and Noteworthy FDA Approvals